May 29, 2018 07:40 AM EDT

ASCO looming, Loxo, Bayer line up a quick shot at FDA OK for their groundbreaking approach to cancer therapy

John Carroll

Editor & Founder

Just days away from learning more about Loxo Oncology’s $LOXO closely-watched cancer drug larotrectinib at ASCO, the company is setting the stage with the news …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ASCO looming, Loxo, Bayer line up a quick shot at FDA OK for their groundbreaking approach to cancer therapy

John Carroll

Editor & Founder

Sign up to read this article for free.

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

Amgen deepens roots in North Carolina with latest $1B factory build

AS­CO loom­ing, Loxo, Bay­er line up a quick shot at FDA OK for their ground­break­ing ap­proach to can­cer ther­a­py

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Biose­cure com­pro­mise could add ex­ec­u­tive re­view process for named com­pa­nies, sources say

Af­ter Unit­ed­Health­care CEO killing, health­care in­dus­try faces a new se­cu­ri­ty re­al­i­ty

Eli­av Barr de­fends Mer­ck­'s LaNo­va deal, but cau­tions VEGF bis­pecifics have yet to de­liv­er ma­ture da­ta

Lil­ly con­tin­ues to ex­pand its em­pire of GLP-1 fac­to­ries with new $3B build­out

GSK's third new pact of the week fo­cus­es on Alzheimer's with start­up Mu­na Ther­a­peu­tics

Am­gen deep­ens roots in North Car­oli­na with lat­est $1B fac­to­ry build

ASCO looming, Loxo, Bayer line up a quick shot at FDA OK for their groundbreaking approach to cancer therapy

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

Amgen deepens roots in North Carolina with latest $1B factory build